Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
about
Design and pre-clinical evaluation of a universal HIV-1 vaccineVaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipientsSynthetic DNA vaccine strategies against persistent viral infectionsDengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral SerotypesIncreased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA VaccineSang Froid in a time of trouble: is a vaccine against HIV possible?A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical TrialDifferent Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope SpecificitySafety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adultsA phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteersPriming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesSafety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in AfricaPlasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Human immunodeficiency virus vaccine trialsEfficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccineCharacterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccineHIV-1 vaccine development after STEP.Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefitSafety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateDNA vaccines: developing new strategies against cancer.Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmissionSafety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.The influence of delivery vectors on HIV vaccine efficacyLong-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.Genetic immunization in the lung induces potent local and systemic immune responses.The T-cell response to HIV.Challenges in the development of an HIV-1 vaccine.DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trialDNA vaccines: ready for prime time?A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominanceSafety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trialDetection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.
P2860
Q21092234-2B18898B-9DB3-42C8-AA40-041C3D301749Q24602593-852DCDD7-16C3-4D3A-9494-16742D72E674Q27016078-F488972D-C9C8-4711-A17A-8F7F8E942CB6Q27304342-159C786A-429B-4E2D-ADCF-0762FF7A211EQ27485003-698080DD-D40E-4B08-A632-7BAEB14F7946Q27487961-E34538A5-AC0F-4172-831C-0C47E4912E22Q27488963-76709B63-E142-4765-8FA0-BCC5A76AEA7EQ27646554-54138A60-A154-418D-B44E-3E991BC2428AQ28740321-E97E45B3-424D-4812-B7C8-CD7221C84F94Q28741673-3C543C56-E2CD-4FAA-98D2-61F53339A4EDQ28744555-6A03EDFC-1974-48B8-BD73-590DFD8C3D43Q28749120-894F0B2F-6A31-4C29-979C-0352EC62A6F8Q28749224-CB8BAFB9-A431-46EC-824D-B60519255FB8Q30369679-6ACBB120-A034-40E6-AB9E-2E80C4CA5C60Q30379200-B978485F-0721-4328-BE8A-F41809CE9F19Q30424366-4AE03F61-CD7D-456C-889C-AA9C1AE10303Q30578618-1D12BEFB-69FD-4554-AC9C-CEF2643E640CQ30982732-CF5DF252-D5F6-4C20-95DB-E684C07874B5Q33527383-ECF51E8F-D4A5-4029-8EED-7DEC8E70B8BDQ33614476-E72DFD37-3810-4389-9939-BD46CE9D1610Q33642318-6FDCCED6-577B-42A7-ABD1-89D67E591CCCQ33698152-37354C23-E752-4B73-81BE-1D9AEAC8E5C5Q33737476-60C5322F-741C-4B91-A225-DC8BB8B62C86Q33749950-32E0EED6-54D0-4BDA-A840-759F5F203817Q33756622-8C39AA79-3E9A-4154-B598-7B289C3918C5Q33875160-3AD0998C-1FD7-4604-87CD-7DA29C70A815Q33936741-1E2335F8-C6D1-4AB6-B32A-2983549D22A3Q34023588-EA7EE683-6F7E-4C12-807E-E7DF5BBCB456Q34077543-47488DD5-104F-4456-979A-3C1C621EA7D3Q34099837-D03228C1-65BF-40A3-A3F9-19AF06520CCEQ34263835-B5F4E1A0-8D49-4898-9E78-7CFB41461CBFQ34438559-0E5D6B77-2D57-42BB-821E-AC19D9D5FD09Q34642996-8F4B7CAA-7097-4C61-AD3D-1005E8E7AF97Q34657290-C9160DCA-FE0E-447E-8F05-5BE37A23432BQ34663554-6D9B1204-3EFE-4925-812D-51B5F2BDC02AQ34824179-23C461CD-0A6F-47E7-975F-5777697101D8Q34833926-B376BD30-7A72-4355-BFA1-C0D259436AB7Q34991038-EBE3647E-42AE-4B2E-A59C-34E7FAAB2089Q35055198-16B998FB-2146-4432-9725-602772C7EBAEQ35060140-D0C8CDA0-CDDD-4715-865E-7D6BA37F32FF
P2860
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
@ast
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
@en
type
label
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
@ast
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
@en
prefLabel
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
@ast
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
@en
P2093
P2860
P50
P356
P1476
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
@en
P2093
Bimal K Chakrabarti
Charla A Andrews
Julie E Martin
Laurie Lamoreaux
Margaret M McCluskey
Mario Roederer
Mary E Enama
Phillip L Gomez
Richard A Koup
Robert T Bailer
P2860
P304
P356
10.1086/509259
P407
P577
2006-11-08T00:00:00Z